Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coya Therapeutics (COYA) EBITDA (2022 - 2025)

Coya Therapeutics (COYA) has disclosed EBITDA for 4 consecutive years, with $12.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 21.96% to $12.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.4 million through Dec 2025, down 36.34% year-over-year, with the annual reading at -$4.4 million for FY2025, 36.34% down from the prior year.
  • EBITDA hit $12.1 million in Q4 2025 for Coya Therapeutics, up from -$2.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $12.1 million in Q4 2025 to a low of -$7.7 million in Q1 2025.
  • Historically, EBITDA has averaged -$1.6 million across 4 years, with a median of -$3.1 million in 2023.
  • Biggest five-year swings in EBITDA: soared 443.36% in 2024 and later plummeted 98.42% in 2025.
  • Year by year, EBITDA stood at -$2.0 million in 2022, then soared by 191.25% to $1.8 million in 2023, then skyrocketed by 443.36% to $9.9 million in 2024, then rose by 21.96% to $12.1 million in 2025.
  • Business Quant data shows EBITDA for COYA at $12.1 million in Q4 2025, -$2.4 million in Q3 2025, and -$6.4 million in Q2 2025.